SecBot SecBot
6-K ·Filed Nov 3, 2026

PHG

KONINKLIJKE PHILIPS NV
NEUTRAL
Impact 5/10
Horizonweeks Processed13d 17h ago SEC0001628280-26-069119
6-K: Earnings release
Actionable Insight • Neutral

The strong order intake (8%) and reiterated guidance suggest underlying demand momentum, but the DOJ settlement provision and ongoing legal overhang cap the upside. Monitor the finalization of the DOJ settlement documentation and the outcome of the State Attorneys General investigation.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Philips reported Q3 2026 results with 3% comparable sales growth (EUR 4.4B) and adjusted EBITA margin expanding 70 bps to 13.0%, driven by strong order intake growth of 8%. The company reiterated its full-year 2026 outlook. A EUR 288 million provision for the Respironics DOJ settlement weighed on GAAP net income, which fell to EUR 28 million from EUR 187 million a year ago.

Key Financial Metrics

EPS (Adj.)
$0.40
GAAP: $0.03
Revenue
$4.4B
est $4.4B · -0.6% · +2.1% YoY
Guidance
3%-4.5% comparable sales growth
maintained
Free Cash Flow
$384.0M
Gross Margin
46.4%

Key Facts

  • Comparable order intake increased 8% in Q3 2026, driven by Diagnosis Treatment.
  • Group sales of EUR 4,393 million, reflecting 3% comparable sales growth.
  • Adjusted EBITA margin improved 70 basis points to 13.0%, with expansion across all segments.
  • Operating cash flow of EUR 544 million, free cash flow of EUR 384 million.
  • Philips recorded a EUR 288 million provision for the Respironics DOJ settlement agreement in principle.
  • GAAP diluted EPS from continuing operations was EUR 0.03, down from EUR 0.19 in Q3 2025.
  • Adjusted diluted EPS from continuing operations was EUR 0.40, up from EUR 0.36 in Q3 2025.
  • Full-year 2026 outlook reiterated: comparable sales growth 3%-4.5%, adjusted EBITA margin 13.5%-14.0%, free cash flow EUR 1.5-1.7 billion.
  • Personal Health comparable sales grew 8%, Connected Care grew 5%, Diagnosis Treatment was flat.
  • Productivity program delivered EUR 170 million in net savings in Q3, on track for EUR 1.5 billion by 2028.

Financial Impact

EUR 288 million Respironics DOJ settlement provision; adjusted EBITA up EUR 38 million to EUR 569 million; free cash flow EUR 384 million vs EUR 172 million a year ago.

net incomeadjusted EBITAfree cash flowEPS

Segment Breakdown

SegmentRevenueGrowth
Diagnosis Treatment$2.1B0.0%
Connected Care$1.2B+5.0%
Personal Health$953.0M+8.0%

Risk Factors

  • Respironics DOJ settlement payment expected in Q1 2027, with further proceedings from State Attorneys General outstanding.
  • China sales weakness in Precision Diagnosis, as previously flagged, may persist.
  • Macro uncertainty and tariff impacts are included in the outlook but could worsen.
  • Activist investor Exor N.V. filed a 13D/A in August 2026, adding governance pressure.

Market Snapshot

Exchange
NYSE
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Analyst Consensus
52% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-069119
Document: 0001628280-26-069119-index-headers.html0001628280-26-069119
Document: 0001628280-26-069119-index.html0001628280-26-069119
Document: 0001628280-26-069119.txt0001628280-26-069119
Earnings Context (Synthetic; results releases only)0001628280-26-069119

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026